Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. (Q40468548)

20 September 2017

Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. (English)

1 reference

20 September 2017

1 reference

Jennifer Williams

1

1 reference

20 September 2017

Peter C Lucas

2

1 reference

20 September 2017

Kent A Griffith

3

1 reference

20 September 2017

Milheon Choi

4

1 reference

20 September 2017

Sarah Fogoros

5

1 reference

20 September 2017

Yuan Yuan Hu

6

1 reference

20 September 2017

J Rebecca Liu

7

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

20 September 2017

1 reference

20 September 2017

96

1 reference

20 September 2017

287-295

1 reference

20 September 2017

2

1 reference

20 September 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Chemotherapy for advanced epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Chemotherapy resistance in ovarian cancer: new molecular perspectives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

The Bcl-2 protein family: arbiters of cell survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Double identity for proteins of the Bcl-2 family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Expression of apoptosis-related proteins is an independent determinant of patient prognosis in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

P53 and Bcl-2 as prognostic predictors in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Bcl-2 expression and prognosis of patients with endometrial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Bcl-xL blocks transforming growth factor-beta 1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Differential expression of antiapoptotic genes in human endometrial carcinoma: bcl-XL succeeds bcl-2 function in neoplastic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Bcl-xL promotes metastasis of breast cancer cells by induction of cytokines resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.10.026

10.1016/J.YGYNO.2004.10.026

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference